Anthem Caps Coverage Of Biogen Spine Drug Despite Wide FDA Approval
Xconomy
JANUARY 24, 2017
One of the nation’s major health insurers has placed limitations on access to the first-ever approved drug for the rare spinal muscular atrophy, validating patient fears that the high price tag of the drug, nusinersen (Spinraza), might make it hard for some with the disease to get treatment.
Let's personalize your content